Haematology
CytoSorbents announces EU launch and availability of PuriFi blood pump
June 14, 2024Medical Communications CytoSorbents, EU, Haematology, PuriFi, blood pump
CytoSorbents Corporation has announced the launch and immediate availability of its PuriFi haemoperfusion machine in the EU following its approval …
FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia
June 7, 2024Medical Communications FDA, Geron, Haematology, anaemia, mds
Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
April 29, 2024Medical Communications FDA, Haematology, Pfizer, haemophilia
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …
Ironic Biotech announces $1m funding to develop iron deficiency and anaemia treatment
April 4, 2024Sales and Marketing Haematology, Ironic Biotech, anaemia, funding, iron deficiency
Swedish biotech startup Ironic Biotech has announced that it has successfully closed a pre-seed funding round of $1m, led by …
AstraZeneca’s Voydeya recommended for approval in EU by CHMP
February 29, 2024Medical Communications AstraZeneca, CHMP, EMA, Haematology, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee …
EC approves Vertex’s Casgevy for sickle cell disease treatment
February 13, 2024Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …
AstraZeneca’s Voydeya approved in Japan for PNH treatment
January 19, 2024Medical Communications AstraZeneca, Haematology, PNH, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in …
FDA approves Novartis’ Fabhalta for PNH treatment
December 6, 2023Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH
Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
Regeneron plans to share advancements from blood cancer pipeline
November 6, 2023Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …
FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis
September 22, 2023Medical Communications FDA, Haematology, Nexcella, amyloidosis
Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NXC-201 for …
GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia
September 18, 2023Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …
FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS
August 30, 2023Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …
Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment
August 21, 2023Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia
Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …
